Pages Menu
Categories Menu

Posted by on Dec 29, 2017 in Foundation NewsLine, Type A, Type B, Type C |

Update from the NNPDF Board

Notification of Intended Pharmaceutical Acquisition

The Board would like to make everyone aware of the planned acquisition of Sucampo Pharmaceuticals by Mallinckrodt Pharmaceuticals, which was announced earlier this week. Click here for more information.